With years of R&D activity, XOMA has built an extensive portfolio of assets, licenses and partner-funded products that we believe to be one of the most diverse product candidate portfolios in biotech.
Our current portfolio of fully funded programs spans multiple stages of the drug development process and across various therapeutic areas. Some of those programs have produced promising preclinical and clinical data. In addition, many of them come from the same discovery engine that has produced successful drugs on the market today.
We have a significant number of licensees to our phage display, antibody discovery and engineering technologies and capabilities. These licenses have been and we believe will continue to be important tools for use by drug discovery scientists, and therefore a source of revenue for the company. By expanding our phage display licensee universe, we continue to fuel an engine that we hope will create valuable milestone and royalty assets in the future.
We currently have a group of assets that are available for out-license. Our intent is to move these assets into the hands of partners who can advance them to bring novel treatment options to patients and to create value for their shareholders. XOMA plans to participate in this value creation as a recipient of any upfront payments, and downstream milestone and royalty payments as these programs advance.